The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective
Open accessAbstract
In the past decade, many tyrosine-kinase inhibitors have been introduced in oncology and haemato-oncology. Because this new class of drugs is extensively used, serious drug-drug interactions are an increasing risk. In this Review, we give a comprehensive overview of known or suspected drug-drug interactions between tyrosine-kinase inhibitors and other drugs. We discuss all haemato-oncological and oncological tyrosine-kinase inhibitors that had been approved by Aug 1, 2013, by the US Food and Drug Administration or the European Medicines Agency. Various clinically relevant drug interactions with tyrosine-kinase inhibitors have been identified. Most interactions concern altered bioavailability due to altered stomach pH, metabolism by cytochrome P450 isoenzymes, and prolongation of the QTc interval. To guarantee the safe use of tyrosine-kinase inhibitors, a drugs review for each patient is needed. This Review provides specific recommendations to guide haemato-oncologists, oncologists, and clinical pharmacists, through the process of managing drug-drug interactions during treatment with tyrosine-kinase inhibitors in daily clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
Impact of OATP transporters on pharmacokinetics
Kalliokoski, A., & Niemi, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00430.x · Cited by 995
Changes in plasma protein binding have little clinical relevance
Benet, L. Z., & Hoener, B. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121829 · Cited by 825
Clinical Pharmacokinetics of Imatinib
Peng, B., Lloyd, P., & Schran, H. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544090-00001 · Cited by 665
Practical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib
Deininger, M. W. N., O’Brien, S. G., Ford, J. M., & Druker, B. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.143 · Cited by 402
Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
MEDINA, P., & GOODIN, S. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.008 · Cited by 377
Drug interactions in cancer therapy
Scripture, C. D., & Figg, W. D. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1887 · Cited by 366
Breedveld, P., Pluim, D., Cipriani, G., Wielinga, P., van Tellingen, O., Schinkel, A. H., & Schellens, J. H. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2416 · Cited by 351
Budha, N. R., Frymoyer, A., Smelick, G. S., Jin, J. Y., Yago, M. R., Dresser, M. J., Holden, S. N., Benet, L. Z., & Ware, J. A. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.73 · Cited by 338
Cited by
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
Self-citationInhibition and induction of CYP enzymes in humans: an update
Hakkola, J., Hukkanen, J., Turpeinen, M., & Pelkonen, O. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02936-7 · Cited by 418
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Deininger, M. W., Shah, N. P., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., DeAngelo, D. J., Gotlib, J., Hobbs, G., Maness, L., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0047 · Cited by 262
Metadata
- Authors
- van Leeuwen, R. W. F., van Gelder, T., Mathijssen, R. H. J., & Jansman, F. G. A.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 15
- Issue
- 8
- Pages
- e315-e326
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2100116917
- Cited by
- 279
- References
- 56
- FWCI
- 22.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective. https://app.cochat.ai/papers/10.1016/s1470-2045(13)70579-5
- The paper
- van Leeuwen, R. W. F., van Gelder, T., Mathijssen, R. H. J., & Jansman, F. G. A. (2014). Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(13)70579-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.